Latest Posters

The mobile phase is a fundamental component of LC-MS analysis, influencing analyte separation, ionization, chromatographic resolution, sensitivity and overall method performance.

With this poster, dive into the world of mass spectrometry troubleshooting, and discover detailed tables listing the accurate mass of elements, organic solvents and potential contaminant ions.

Biolayer Interferometry (BLI) technology has greatly advanced the process of antibody discovery, and the latest platforms offer reliable, high precision analysis which researchers can rely on.

Despite the valuable transcriptomic information provided by probe-based spatial assays, detecting immune cell infiltration can pose challenges

There is more to DNA than A, C, G and T, epigenetics plays a causal role in cell fate, aging and disease development. Genetic and methylation data together on the same read allow us to get a more complete picture of genome biology. Constrained to measuring four states of information, existing NGS- based technologies sacrifice genetic for methylation calling.

Liquid biopsy for profiling of cell free DNA (cfDNA) in blood holds huge promise to transform how we experience and manage cancer by early detection and identification of residual disease and subtype. However, a standard blood draw yields an average of only 10 ng of cfDNA, of which DNA derived from the tumor is a small minority.

Designing and performing assays that accurately measure small molecule binding kinetics is an important part of the drug discovery process. It allows researchers to predict the efficacy of potential novel therapeutics and make quick decisions about weak binders.

This poster demonstrates how a novel, precise and highly controlled iPSC reprogramming technology overcomes these limitations and enables the generation of mature cell types and isogenic models of neurodegenerative disease.

Many promising drugs which show efficacy in animal models have failed in the clinic due to interspecies variance in nociception mechanisms. Hence, consistent, scalable human in vitro models are required to accelerate potential therapeutics to the clinic.

While animal models and primary cells remain valuable resources, neuronal drug development faces many challenges. Not least, the variability and inaccuracy of traditional model systems can result in the failure to translate data into successful clinical trials.